VIMIAN Share Price Performance
SEK 0
-41.76 (-100.00%)
Price SEK 0
Fair ValueSEK 26.50
Share Pricen/a
Narrative Update • Jun 30
Vimian Group AB (publ) Stock Price
- 3 Narratives written by author
- 0 Comments on narratives written by author
- 3 Fair Values set on narratives written by author
VIMIAN Community Narratives
AN
Fair Value
·Fair Value SEK 26.5 13.8% overvalued intrinsic discount
Rising Interest Rates And Tariffs Will Weaken US MedTech Margins
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
Fair Value
·Fair Value SEK 41.03 26.5% undervalued intrinsic discount
Emerging Pet Trends And Digital Diagnostics Will Redefine Animal Healthcare
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
Fair Value
·Fair Value SEK 34.98 13.8% undervalued intrinsic discount
Digital Adoption And Niche Expansion Will Empower Veterinary Healthcare
0users have liked this narrative
0users have commented on this narrative
2users have followed this narrative
Rising Interest Rates And Tariffs Will Weaken US MedTech Margins
Vimian rides long-term demand for animal health, but its deal-heavy growth and debt could start to bite as borrowing gets pricier and trade rules shift. See why tariffs, softer demand in parts of the U.S. business, and rising pressure from bigger clinic groups may make the company’s growth look less predictable than many expect.Read more
AN
SEK 26.5
13.8% overvalued intrinsic discount
Fair Value
Revenue
10.13% p.a.
Profit Margin
11.62%
Future PE
22.26x
Price in 2029
SEK 31.49
Emerging Pet Trends And Digital Diagnostics Will Redefine Animal Healthcare
Vimian bets on a wave of pet owners spending more on advanced care, with new diagnostics and specialty medicines helping it grow beyond its current markets. The upside comes with strings attached: heavy deal-making, tougher rules, and softer demand for non-urgent vet procedures could all squeeze results.Read more
AN
SEK 41.03
26.5% undervalued intrinsic discount
Fair Value
Revenue
11.66% p.a.
Profit Margin
15.16%
Future PE
25.77x
Price in 2029
SEK 48.73
Digital Adoption And Niche Expansion Will Empower Veterinary Healthcare
Key Takeaways Sustained demand for advanced veterinary care and expansion in niche, high-margin segments position Vimian for recurring revenue and profit growth. Strategic acquisitions, digital adoption, and operational improvements support increased market share, new growth avenues, and recovery in underperforming areas.Read more
AN
SEK 34.98
13.8% undervalued intrinsic discount
Fair Value
Revenue
10.29% p.a.
Profit Margin
14.38%
Future PE
24.69x
Price in 2029
SEK 41.73
Trending Discussion
Recently Updated Narratives
AN
VIMIAN: Lower Margin Outlook Will Limit Future Share Price Upside
Fair Value: SEK 26.5 13.8% overvalued intrinsic discount
0 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
VIMIAN: Lower Discount Rate And New Bylaws Will Support Future Repricing
Fair Value: SEK 41.03 26.5% undervalued intrinsic discount
0 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
VIMIAN: Margin Execution And Governance Changes Will Support Future Upside Potential
Fair Value: SEK 34.98 13.8% undervalued intrinsic discount
2 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Vimian Group AB (publ) Key Details
Last Reported Earnings
Mar 31, 2026
Next Reporting Earnings
Jul 17, 2026
- 0.07
- 69.00%
- 8.49%
- 31.5%
About VIMIAN
- Founded
- 2020
- Employees
- 1300
- CEO
- WebsiteView website
Vimian Group AB (publ) engages in the animal health business worldwide. It operates through four segments: Specialty Pharma, MedTech, Diagnostics, and Veterinary Services. The company offers proprietary diagnostics, prescription, and non-prescription treatments for preventive care and treatment of chronic conditions for companion animals under the Nextmune brand name; and molecular and immunodiagnostic solutions that are used by laboratories for veterinary specific applications with a focus on livestock and companion animal health markets under the Indical Bioscience brand name. It also provides procurement and tech-driven operations, such as online marketing, education, and HR, as well as a community for veterinary clinics through a membership-based platform under the VetFamily brand name; and surgical and dental products to veterinary clinics and universities, including dentistry and companion animal orthopedics under the Movora brand name. Vimian Group AB (publ) was incorporated in 2020 and is headquartered in Stockholm, Sweden.
Recent VIMIAN News & Updates
Narrative Update • Jun 16
